title: Metastasectomy for gastrointestinal stromal tumors.
abstract: Gastrointestinal stromal tumor (GIST) is the most common sarcoma of the intestinal tract. Improvements in understanding the molecular pathogenesis of GIST have resulted in novel treatment strategies combining surgery with tyrosine kinase inhibitors (TKIs). Metastasectomy in carefully selected patients who have stable or responsive disease on imatinib should be considered in the multidisciplinary setting. We review existing data on surgical cytoreduction in metastatic GIST while on targeted therapy and compare outcomes with either treatment alone.
authors.affiliation: Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York.
authors.forename: Zubin M
authors.initials: ZM
authors.lastname: Bamboat
authors.forename: Ronald P
authors.initials: RP
authors.lastname: DeMatteo
mesh_terms: D001549:Benzamides / Q000627:therapeutic use; D005770:Gastrointestinal Neoplasms / Q000473:pathology*; D046152:Gastrointestinal Stromal Tumors / Q000556:secondary* / Q000601:surgery*; D006801:Humans; D000068877:Imatinib Mesylate; D059146:Metastasectomy / Q000379:methods*; D009154:Mutation; D018579:Patient Selection; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate
keywords: KIT; gastrointestinal stromal tumor; metastasectomy; tyrosine kinase